Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Sponsor: Palvella Therapeutics, Inc.
Summary
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2024-12-20
Completion Date
2026-03
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
QTORIN 3.9% rapamycin anhydrous gel
QTORIN 3.9% Rapamycin Anhydrous Gel
Locations (10)
Children's Hospital of Orange County
Irvine, California, United States
Stanford University
Palo Alto, California, United States
Colorado Children's Hospital
Aurora, Colorado, United States
Johns Hopkins
Baltimore, Maryland, United States
Minnesota Clinical Study Center
New Brighton, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Utah Health
Salt Lake City, Utah, United States